The Office of Cancer Clinical Proteomics Research of the National Cancer Institute (NCI) has awarded $ 4.2 million over five years to Mount Sinai researchers establishing a Proteogenomic Data Analysis Center (PGDAC) to advance cancer research and treatments. Proteogenomics, which studies the role of proteins and genes within a cell or organism, is a crucial area of exploration to deepen our understanding of cancer.
The award supports the Centre’s work to identify potential biomarkers and targets for cancer drugs, new ideas on cancer biology, and bioinformatics tools to enable more advanced exploration and discovery from cancer-related data sets. .
The center’s principal investigators, Pei Wang, PhD, Professor, Genetic and Genomic Sciences, and Avi Ma’ayan, PhD, Professor of Pharmacological Sciences and Director of the Mount Sinai Center for Bioinformatics, will leverage their experience in statistics / biostatistics, machine. learning, data integration, systems pharmacology, and proteomics data modeling to better understand the proteogenomic complexity of tumors.
The centers of excellence are part of the NCI’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) program, a national effort to advance and accelerate cancer research through the application of proteogenomics. Mount Sinai is one of 14 CPTAC centers nationwide.
The data generated and the tools developed by the CPTAC centers will be made available to the public to help advance and accelerate cancer research.
Source:
Mount Sinai health system